BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052

Reuters02-24

BRIEF-<a href="https://laohu8.com/S/ACRS">Aclaris Therapeutics</a> Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052

Feb 24 (Reuters) - Aclaris Therapeutics Inc ACRS.O:

ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ASTHMA WITH ITS NOVEL BISPECIFIC ANTI-TSLP/IL-4RΑ ANTIBODY ATI-052
ACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026
ACLARIS THERAPEUTICS INC - PHASE 2B PROGRAM ENCOMPASSING ASTHMA AND ATOPIC DERMATITIS EXPECTED TO START IN H2 2026

Source text: ID:nGNX5Ywq8Y

Further company coverage: ACRS.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613716653?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-24 20:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613716653","market":"fut","top_or_hot":-1,"title":"BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052</title></head><body><p><span>Feb 24 (Reuters)</span><span> - </span>Aclaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>ACRS.O</span>:</p><ul><li><p>ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ASTHMA WITH ITS NOVEL BISPECIFIC ANTI-TSLP/IL-4RΑ ANTIBODY ATI-052</p></li><li><p>ACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026</p></li><li><p>ACLARIS THERAPEUTICS INC - PHASE 2B PROGRAM ENCOMPASSING ASTHMA AND ATOPIC DERMATITIS EXPECTED TO START IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNX5Ywq8Y</span></p><p>Further company coverage: <span>ACRS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-24 20:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/ACRS\">Aclaris Therapeutics</a> Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052</title></head><body><p><span>Feb 24 (Reuters)</span><span> - </span>Aclaris <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc <span>ACRS.O</span>:</p><ul><li><p>ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ASTHMA WITH ITS NOVEL BISPECIFIC ANTI-TSLP/IL-4RΑ ANTIBODY ATI-052</p></li><li><p>ACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026</p></li><li><p>ACLARIS THERAPEUTICS INC - PHASE 2B PROGRAM ENCOMPASSING ASTHMA AND ATOPIC DERMATITIS EXPECTED TO START IN H2 2026</p></li></ul><p>Source text: <span>ID:nGNX5Ywq8Y</span></p><p>Further company coverage: <span>ACRS.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ACRS","symbol_name":"Aclaris Therapeutics","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nTUA5ND25V:1","article_id":"2613716653","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2613716653","pubTimestamp":1771935502,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052Feb 24 (Reuters) - Aclaris Therapeutics Inc ACRS.O:ACLARIS THERAPEUTICS IN","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ACRS":"Aclaris Therapeutics","BK4007":"制药"},"translate_title":"简介-Aclaris Therapeutics启动其新型双特异性抗Tslp/IL-4R α抗体Ati-052的1B期概念验证试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACRS":0.9},"content_text":"BRIEF-Aclaris Therapeutics Initiates Phase 1B Proof-Of-Concept Trial Of Its Novel Bispecific Anti-Tslp/Il-4Rα Antibody Ati-052Feb 24 (Reuters) - Aclaris Therapeutics Inc ACRS.O:ACLARIS THERAPEUTICS INITIATES PHASE 1B PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ASTHMA WITH ITS NOVEL BISPECIFIC ANTI-TSLP/IL-4RΑ ANTIBODY ATI-052ACLARIS THERAPEUTICS INC - TOP LINE RESULTS EXPECTED IN SECOND HALF OF 2026ACLARIS THERAPEUTICS INC - PHASE 2B PROGRAM ENCOMPASSING ASTHMA AND ATOPIC DERMATITIS EXPECTED TO START IN H2 2026Source text: ID:nGNX5Ywq8YFurther company coverage: ACRS.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613716653","isCrawlerRequest":true}